Literature DB >> 27252513

How to select the best available related or unrelated donor of hematopoietic stem cells?

Jean-Marie Tiercy1.   

Abstract

Recognition of HLA incompatibilities by the immune system represents a major barrier to allogeneic hematopoietic stem cell transplantation. HLA genotypically identical sibling donors are, therefore, the gold standard for transplantation purposes, but only 30% patients have such a donor. For the remaining 70% patients alternative sources of stem cells are a matched unrelated adult volunteer donor, a haploidentical donor or a cord blood unit. The definition of 'HLA matching' depends on the level of resolution and on which loci are tested. The development of HLA molecular typing technologies and the availability of more than 27 million donors in the international database has greatly facilitated unrelated donor searches. The gold standard is high resolution typing at the HLA-A, -B, -C, -DRB1, and -DQB1 loci (10/10 match). Single disparities for HLA-A, -B, - C, or -DRB1 are associated with increased risk of post-transplant complications, but less so in patients with advanced disease, and in those undergoing T-cell-depleted allografting. HLA-DQB1 mismatches seem to be better tolerated and some HLA-C, -DRB1 and -DPB1 disparities are potentially less immunogenic. HLA typing by next-generation sequencing methods is likely to change matching algorithms by providing full sequence information on all HLA loci in a single step. In most European populations a 10/10 matched donor can be found for at least 50% of patients and an additional 20-30% patients may have a 9/10 matched donor. Genetic factors that help in identifying donors with less immunogenic mismatches are discussed. Haploidentical donors are increasingly used as an alternative source of stem cells for those patients lacking a matched unrelated donor. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27252513      PMCID: PMC5013969          DOI: 10.3324/haematol.2015.141119

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  66 in total

1.  Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.

Authors:  Joseph Pidala; Tao Wang; Michael Haagenson; Stephen R Spellman; Medhat Askar; Minoo Battiwalla; Lee Ann Baxter-Lowe; Menachem Bitan; Marcelo Fernandez-Viña; Manish Gandhi; Ann A Jakubowski; Martin Maiers; Susana R Marino; Steven G E Marsh; Machteld Oudshoorn; Jeanne Palmer; Vinod K Prasad; Vijay Reddy; Olle Ringden; Wael Saber; Stella Santarone; Kirk R Schultz; Michelle Setterholm; Elizabeth Trachtenberg; E Victoria Turner; Ann E Woolfrey; Stephanie J Lee; Claudio Anasetti
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

Review 2.  Selection of optimal alternative graft source: mismatched unrelated donor, umbilical cord blood, or haploidentical transplant.

Authors:  Karen K Ballen; John Koreth; Yi-Bin Chen; Bimalangshu R Dey; Thomas R Spitzer
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

Review 3.  Search for an unrelated HLA-compatible stem cell donor.

Authors:  E Roosnek; J M Tiercy
Journal:  Curr Opin Hematol       Date:  1999-11       Impact factor: 3.284

4.  Sequencing of two HLA-A blank alleles: implications in unrelated bone marrow donor matching.

Authors:  R Zanone-Ramseier; A Gratwohl; J Gmür; E Roosnek; J M Tiercy
Journal:  Transplantation       Date:  1999-05-27       Impact factor: 4.939

Review 5.  The impact of HLA genotyping on survival following unrelated donor haematopoietic stem cell transplantation.

Authors:  Bronwen E Shaw; Rafael Arguello; Christian A Garcia-Sepulveda; J Alejandro Madrigal
Journal:  Br J Haematol       Date:  2010-06-15       Impact factor: 6.998

6.  HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.

Authors:  Effie W Petersdorf; Theodore A Gooley; Mari Malkki; Andrea P Bacigalupo; Anne Cesbron; Ernette Du Toit; Gerhard Ehninger; Torstein Egeland; Gottfried F Fischer; Thibaut Gervais; Michael D Haagenson; Mary M Horowitz; Katharine Hsu; Pavel Jindra; Alejandro Madrigal; Machteld Oudshoorn; Olle Ringdén; Marlis L Schroeder; Stephen R Spellman; Jean-Marie Tiercy; Andrea Velardi; Campbell S Witt; Colm O'Huigin; Richard Apps; Mary Carrington
Journal:  Blood       Date:  2014-10-16       Impact factor: 22.113

7.  Lack of recognition of HLA class I mismatches outside α1/α2 domains by CD8+ alloreactive T lymphocytes: the HLA-B44 paradigm.

Authors:  F Bettens; U Schanz; J-M Tiercy
Journal:  Tissue Antigens       Date:  2013-03-14

8.  Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.

Authors:  Marcelo A Fernández-Viña; John P Klein; Michael Haagenson; Stephen R Spellman; Claudio Anasetti; Harriet Noreen; Lee Ann Baxter-Lowe; Pedro Cano; Neal Flomenberg; Dennis L Confer; Mary M Horowitz; Machteld Oudshoorn; Effie W Petersdorf; Michelle Setterholm; Richard Champlin; Stephanie J Lee; Marcos de Lima
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

9.  Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?

Authors:  Sergio Querol; Ghulam J Mufti; Steven G E Marsh; Antonio Pagliuca; Ann-Margaret Little; Bronwen E Shaw; Robert Jeffery; Joan Garcia; John M Goldman; J Alejandro Madrigal
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

10.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

View more
  39 in total

1.  Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.

Authors:  A Garnier; T Guillaume; P Peterlin; M C Béné; Y Le Bris; V Dubruille; B Mahé; T Gastinne; C Touzeau; N Blin; S Le Gouill; P Moreau; P Chevallier
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

2.  High-resolution characterization of allelic and haplotypic HLA frequency distribution in a Spanish population using high-throughput next-generation sequencing.

Authors:  Gonzalo Montero-Martín; Kalyan C Mallempati; Sridevi Gangavarapu; Francisco Sánchez-Gordo; Maria J Herrero-Mata; Antonio Balas; Jose L Vicario; Florentino Sánchez-García; Maria F González-Escribano; Manuel Muro; Maria R Moya-Quiles; Rafael González-Fernández; Javier G Ocejo-Vinyals; Luis Marín; Lisa E Creary; Kazutoyo Osoegawa; Tamara Vayntrub; Jose L Caro-Oleas; Carlos Vilches; Dolores Planelles; Marcelo A Fernández-Viña
Journal:  Hum Immunol       Date:  2019-02-11       Impact factor: 2.850

Review 3.  Diagnostic molecular techniques in haematology: recent advances.

Authors:  Aikaterini Koutsi; Elisavet-Christina Vervesou
Journal:  Ann Transl Med       Date:  2018-06

4.  Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide.

Authors:  Lisa V E Oostenbrink; Emma S Pool; Cornelia M Jol-van der Zijde; Anja M Jansen-Hoogendijk; Carly Vervat; Astrid G S van Halteren; Robbert G M Bredius; Frans J W Smiers; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester; Alexander B Mohseny
Journal:  Bone Marrow Transplant       Date:  2021-05-03       Impact factor: 5.483

5.  Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: Linkage analysis of over 32,000 samples.

Authors:  Bianca Schöne; Sabine Bergmann; Kathrin Lang; Ines Wagner; Alexander H Schmidt; Effie W Petersdorf; Vinzenz Lange
Journal:  Hum Immunol       Date:  2017-11-07       Impact factor: 2.850

6.  The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Authors:  Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Bone Marrow Transplant       Date:  2020-06-18       Impact factor: 5.483

7.  Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching.

Authors:  Katharina Fleischhauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

Authors:  R Parody; I Sánchez-Ortega; A Mussetti; B Patiño; M Arnan; H Pomares; E González-Barca; S Mercadal; C Boqué; C Maluquer; I Carro; M Peña; V Clapés; S Verdesoto; G Bustamante; A C Oliveira; C Baca; E Cabezudo; C Talarn; L Escoda; S Ortega; N García; M Isabel González-Medina; Mar Sánchez-Salmerón; C Fusté; J Villa; E Carreras; E Domingo-Domènech; A Sureda
Journal:  Bone Marrow Transplant       Date:  2021-10-28       Impact factor: 5.483

9.  Serine protease inhibitor 6 protects alloreactive T cells from Granzyme B-mediated mitochondrial damage without affecting graft-versus-tumor effect.

Authors:  Wei Du; Hemn Mohammadpour; Rachel E O'Neill; Sandeep Kumar; Chuan Chen; Michelle Qiu; Lin Mei; Jingxin Qiu; Philip L McCarthy; Kelvin P Lee; Xuefang Cao
Journal:  Oncoimmunology       Date:  2017-11-16       Impact factor: 8.110

10.  The effect of NIMA matching in adult unrelated mismatched hematopoietic stem cell transplantation - a joint study of the Acute Leukemia Working Party of the EBMT and the CIBMTR.

Authors:  Julia Pingel; Tao Wang; Yvonne Hagenlocher; Camila J Hernández-Frederick; Arnon Nagler; Michael D Haagenson; Katharina Fleischhauer; Katharine C Hsu; Michael R Verneris; Stephanie J Lee; Mohamad Mohty; Emmanuelle Polge; Stephen R Spellman; Alexander H Schmidt; Jon J van Rood
Journal:  Bone Marrow Transplant       Date:  2018-10-02       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.